VistaGen Therapeutics Inc./$VTGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Ticker
$VTGN
Sector
Primary listing
Employees
59
Headquarters
Website
VTGN Metrics
BasicAdvanced
$27m
-
-$1.89
0.29
-
Price and volume
Market cap
$27m
Beta
0.29
52-week high
$5.14
52-week low
$0.43
Average daily volume
1m
Financial strength
Current ratio
4.675
Quick ratio
4.566
Long term debt to equity
0.846
Total debt to equity
2.802
Profitability
EBITDA (TTM)
-69.717
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-8,497.59%
Operating margin (TTM)
-8,859.82%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-55.53%
Return on equity (TTM)
-101.55%
Valuation
Price to revenue (TTM)
30.943
Price to book
0.54
Price to tangible book (TTM)
0.54
Price to free cash flow (TTM)
-0.403
Free cash flow yield (TTM)
-247.97%
Free cash flow per share (TTM)
-1.711
Growth
Revenue change (TTM)
13.04%
Earnings per share change (TTM)
22.65%
3-year revenue growth (CAGR)
29.42%
3-year earnings per share growth (CAGR)
-41.05%
10-year earnings per share growth (CAGR)
-46.02%
VTGN News
AllArticlesVideos
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Business Wire·3 days ago
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Business Wire·1 month ago
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs